Company news
Solid Biosciences Inc. (NASDAQ:SLDB) news
Solid Biosciences Inc. news releases on 6ix. Latest, Oct 1, 2026: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2026
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
June 2, 2026
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
May 12, 2026
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
May 7, 2026
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
April 30, 2026
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
April 27, 2026
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 18, 2026
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
March 10, 2026
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
March 5, 2026
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
February 9, 2026
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 6, 2026
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
January 13, 2026
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
January 12, 2026
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
January 12, 2026
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 5, 2026
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
December 16, 2025
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
December 8, 2025
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
December 1, 2025
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
November 17, 2025
Solid Biosciences to Participate at Upcoming Investor Conferences
November 11, 2025
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
November 6, 2025
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
November 3, 2025
Solid Biosciences to Present at Upcoming Scientific Meetings
October 1, 2025
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
September 25, 2025
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101
September 23, 2025
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 12, 2025
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
July 23, 2025
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
July 21, 2025
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
July 8, 2025
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference
May 28, 2025
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
May 15, 2025
Solid Biosciences to Participate at The Citizens Life Sciences Conference
April 30, 2025
Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting
April 29, 2025
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 12, 2025
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 6, 2025
Solid Biosciences Announces Pricing of Underwritten Offering
February 18, 2025
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
February 18, 2025
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
January 20, 2025
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
January 14, 2025
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
January 6, 2025
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
December 3, 2024
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 5, 2024
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 4, 2024
Solid Biosciences Joins the Russell 3000® Index
June 30, 2024
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
May 14, 2024
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
March 31, 2024
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
March 12, 2024
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
March 6, 2024